ANALYSIS AND NEWS
l For a given lead candidate, what are known adverse effects of similar compounds?
l Obtain a reliable and comprehensive picture of the information available regarding negative events and other clinical risks.
l Do similar compounds have side effects that might suggest repurposing for alternative therapeutic uses? and
l Rapidly identify areas of intervention and better understand causal factors, while monitoring the results of clinical events. Semantic analysis discovers what is contained in content, understanding the meaning and context, and dramatically improving an organisation’s ability to use all information available.
Life science and pharmaceutical companies can ensure the highest level of precision and recall in ensuring quick and accurate response to FDA requirements, and improve knowledge management of all their information assets. A solution based on semantic analysis can provide powerful
‘Innovations rarely come out of a vacuum’
automated disambiguation, classification, entity extraction and metadata to classify research content automatically, monitor feedback on drugs, gather physician comment and experience for future drug developments, and verify the strategies employed by sales and distribution channels. Answers to questions such as these may optimise the effectiveness of R&D organisations by accelerating innovation cycles and avoiding costly dead-ends.
Boost market intelligence In the pharmaceutical industry – due to the combined onslaught of increasing regulatory pressure and sustained competition from generics – the traditional product development strategy rooted in fundamental research has become more cut-throat, and the corresponding pipelines are drying up. Similar trends are at play in other segments of the larger life sciences industry. More emphasis has now shifted to alternative strategies involving external growth capitalisation on intellectual property. In this context, it is essential for organisations to: l Track competitors’ business development
www.researchinformation.info @researchinfo AUGUST/SEPTEMBER 2016 Research Information 11 including partnerships and licensing;
l Identify relevant acquisition targets with promising pipelines;
l Gather competitive intelligence about business, communication, and research strategy;
l Leverage the FDA website to extract competitive information of approval process and phase, understand which drugs are approved, which are not approved, and why, in order to identify virgin or underexploited areas of interest through white spot analyses;
l Maintain real-time awareness of regulatory evolutions;
l Minimise intellectual property infringement risks and associated legal costs; and
l Detect sentiment relating to product or brand by understanding opinions.
Stay ahead of the competition Each organisation’s view of the competition is specific to its own portfolio and business strategies. To identify trends, opportunities and threats, researchers and decision makers will turn to a wide selection of information sources, including scientific publications, patents, news, clinical reports and user generated content. Effective competitive intelligence (CI) requires sources that are semantically enriched, normalised, inter-connected and made available in a centralised location. The benefits of such an approach in the pharmaceutical industry include:
l Up-to-date and relevant information on publications, patents, clinical trials, experts, news and pharmacovigilance for informed decision making;
l CI experts spend less time looking for information and more time analysing search results;
l A solution that provides access to hitherto untapped information with the ability to charting clinical trials landscape, including related news and results;
l Identifying experts as revealed by their publication metrics and collaboration networks;
l Mining news and research for the latest scientific and biopharma business news (scientific discoveries, drug approvals, trials, regulatory news, conferences, and deals) and extract information from online publication repositories such as Medline, NIH Projects, and patents; and
l Dynamic, timely information based on databases built around deep linking, revealing previously undiscovered connections, in real time.
The pharmaceutical and life sciences industry are a good example of the value taxonomies and ontologies can generate in bringing order to the vast universe of available content. Semantic analysis can be of great value in understanding the meaning and context of information, and dramatically improve its usability.
Allan Gajadhar is senior sales engineer at Expert System Enterprise
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32
